

Table S2. Scoring of Benlysta according to different criteria, as visualised in the decision tree. FE and UFE are favourable and unfavourable effects, respectively. SRI is SLE Response Index, SLEDAI is SLE Disease Activity Index, PGA is Physician’s Global Assessment, BILAG is British Isles Lupus Assessment Group, where A indicates severe disease and B less active disease. Secondary favourable endpoints are CS, corticosteroids, Flare rate meaning number of new BILAG A cases and QoL measured as mean change in the total score of Short Form 36. SAE are serious adverse events, such as tumour development, opportunistic infections or progressive multifocal leukoencephalopathy (PML). * > 25% and to less than 7.5 mg/day, ** per patient year. Based on [50].

Effects	Name	Description	Best	Worst	Units	Placebo	10 mg	1 mg	
Favourable	SRI	SLEDAI	Improved ≥ 4	100	0	%	41	53	48
		PGA	No worsening	100	0	%	66	75	76
		PGA	Mean change	1	0	Difference	0,44	0,48	0,45
		BILAG	No new A/2B	100	0	%	69	75,2	70,1
	Secondary endpoints	CS sparing	Dose reduction*	100	0	%	12,3	17,5	20
		Flare rate	New BILAG A cases**	0	5	Frequency	3,51	2,88	2,9
		QoL	Mean change SF36	0	100	Difference	3,5	3,4	3,7
Unfavourable	SAE	Potential	100	0		100	0	90	
	Infections	Life-threatening infections	0	10	%	5,2	5,2	6,8	
	Sensitivity reaction	Hypersensitivity reactions	0	2	%	0,1	0,4	0,3	